Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | FOLH1 | Q04609 | 7/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | SLC9A3 | P48764 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14728245 | 1.00 | HPGD (0.36) | HPGDHTTSMN1; SMN2DRD2FOLH1 | |
| SCHEMBL14728251 | 0.92 | SMN1; SMN2 (0.46) | HPGDHTTSMN1; SMN2DRD2OPRK1 | |
| SCHEMBL13056342 | 0.90 | SMN1; SMN2 (0.37) | HPGDHTTSMN1; SMN2DRD2FOLH1 | |
| SCHEMBL17357524 | 0.90 | SMN1; SMN2 (0.37) | HPGDHTTSMN1; SMN2DRD2FOLH1 | |
| SCHEMBL13776353 | 0.89 | SMN1; SMN2 (0.36) | HPGDHTTSMN1; SMN2DRD2FOLH1 | |
| SCHEMBL13056345 | 0.89 | SMN1; SMN2 (0.37) | HPGDHTTSMN1; SMN2DRD2FOLH1 | |
| SCHEMBL24686922 | 0.89 | SMN1; SMN2 (0.47) | HPGDHTTSMN1; SMN2DRD2FOLH1 | |
| SCHEMBL18264887 | 0.89 | SMN1; SMN2 (0.37) | HPGDHTTSMN1; SMN2DRD2OPRK1 | |
| SCHEMBL19599627 | 0.89 | TP53 (0.37) | HPGDHTTSMN1; SMN2DRD2OPRK1 | |
| SCHEMBL13248131 | 0.88 | SMN1; SMN2 (0.35) | HPGDHTTSMN1; SMN2DRD2FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130052130-A1 | Branched Discreet PEG Constructs | UNIVERSITY OF WASHINGTON (US) | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130052130-A1 | Branched Discreet PEG Constructs | BTD, DNPEP, IDUA | HPGD 734/4885HTT 3476/4885SMN1; SMN2 3611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.